SAN DIEGO, California--Imagenetix has announced publication of a second study conducted on its proprietary compound, 1-TDC, for the treatment of periodontal disease.
Dr. Hatice Hasturk, DDS, PhD. from Boston University's Department of Periodontology and Oral Biology led the investigative team. The study was published in the July issue of the Journal of Periodontology (J Periodontal 2009; 80(7):1103-13).
In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.
"The results of this experiment are very exciting and demonstrate the great promise that 1-TDC offers in the treatment of periodontal disease," stated Dr. Hasturk.
"These findings clearly demonstrate that 1-TDC reverses, at least in part, the damage associated with experimental periodontitis," he added. "We look forward to continuing our work with Imagenetix as they move towards the path of a new drug application and progressive drug development with the FDA."
Commenting on the results of the study, William P. Spencer, president of Imagenetix said, "1-TDC is a promising early stage drug for the treatment of periodontitis. We now have two published animal studies showing clear evidence of efficacy and we continue to position our 1-TDC for a phase 1 trial with the FDA. In addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected Clinical Research Organization to provide Imagenetix specific time lines to achieve drug approval from the FDA."
For more information, go to Imagenetix.
To read more about Boston University, go to Boston University.
To comment on this topic, go to PennWell Dental Community site.